Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease

Hum Gene Ther. 2000 Jul 1;11(10):1465-75. doi: 10.1089/10430340050057530.

Authors

H Heslop¹, C Rooney, M Brenner, R Krance, G Carrum, B Gahn, C Bollard, S Khan, A Gee, U Popat, M Gresik, D Przepiorka, I Kuehnle, B Grilley

Affiliation

¹ Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston 77030-2399, USA.

PMID: 10910143
DOI: 10.1089/10430340050057530

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I

MeSH terms

Bone Marrow Transplantation / methods*
Cell Line
Drug Resistance, Neoplasm / genetics*
Feasibility Studies
Female
Genetic Therapy*
Herpesvirus 4, Human / genetics*
Herpesvirus 4, Human / immunology
Hodgkin Disease / therapy*
Humans
Male
Neomycin / metabolism*
Recurrence
T-Lymphocytes, Cytotoxic / metabolism*

Substances

Neomycin